In the week between Sunday 28 February and Saturday 6 March, 677 companies operating in the pharma space posted 12,040 jobs, according to GlobalData’s jobs analytics tool. This represents an 8% decrease on the week prior, 21 to 27 February, when 13,098 jobs were posted.
Of the 12,040 jobs posted in the first week of March, 8,699 (72%) were classified as entry or junior level jobs. Companies hiring at this level include Amgen, Johnson & Johnson (J&J) and Gilead. Digital media, marketing and sales dominated recruitment at the entry and junior level this week.
There were only 764 jobs posted at the senior level between 28 February and 6 March. Gilead and J&J were also recruiting at this level, but a standout company was AbbVie, which was hiring 25 jobs at this level. Examples include global medical affairs director of ophthalmology and executive director of regulatory affairs.
Ophthalmology and eye care are areas of focus for AbbVie. This element of its business has only strengthened since AbbVie acquired Allergan in May 2020. In addition, AbbVie and Allergan are very active in filing for US Food and Drug Administration (FDA) approvals. At the end of February, AbbVie received US approval for its lead product Humira (adalimumab) in ulcerative colitis (UC).
Recruitment drives from Takeda and J&J
J&J had another productive week of hiring at the beginning of March. On the back of posting 462 jobs last week, between the 28 February and 6 March the US pharma giant posted 437 jobs.
The company focused its hiring in the US where it posted 190 positions. These included a senior manager for external Covid-19 planning, as well as a global strategic marketing manager. J&J’s Covid-19 vaccine is now approved by the US FDA and Health Canada, and the European Medicines Agency is currently reviewing a conditional marketing authorisation application for the vaccine.
Japanese-headquartered Takeda was also on a hiring spree. In the first week of March, the company posted 245 jobs; the week prior, Takeda had posted 291 jobs.
Between 28 February and 6 March, Takeda focused its hiring in Europe and Asia-Pacific. Most of these jobs were at the entry or junior level.
Across Asia-Pacific, Takeda was particularly hiring for medical communications representatives for certain therapy areas or drugs. For instance, the company was recruiting for representatives for Entyvio in a few Chinese cities. Entyvio (vedolizumab) is a monoclonal antibody therapy indicated for UC and Crohn’s disease; the drug was approved by the EMA in May 2020 and by Chinese authorities in March 2020. According to Takeda’s full year 2020 report, Entyvio was central to the company’s revenue growth last year.